These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 16488988)

  • 21. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.
    Dutoit V; Rubio-Godoy V; Dietrich PY; Quiqueres AL; Schnuriger V; Rimoldi D; Liénard D; Speiser D; Guillaume P; Batard P; Cerottini JC; Romero P; Valmori D
    Cancer Res; 2001 Aug; 61(15):5850-6. PubMed ID: 11479225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1.
    Ayyoub M; Zippelius A; Pittet MJ; Rimoldi D; Valmori D; Cerottini JC; Romero P; Lejeune F; Liénard D; Speiser DE
    Clin Cancer Res; 2003 Feb; 9(2):669-77. PubMed ID: 12576434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.
    Smith JW; Walker EB; Fox BA; Haley D; Wisner KP; Doran T; Fisher B; Justice L; Wood W; Vetto J; Maecker H; Dols A; Meijer S; Hu HM; Romero P; Alvord WG; Urba WJ
    J Clin Oncol; 2003 Apr; 21(8):1562-73. PubMed ID: 12697882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
    Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
    Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.
    Jandus C; Bioley G; Dojcinovic D; Derré L; Baitsch L; Wieckowski S; Rufer N; Kwok WW; Tiercy JM; Luescher IF; Speiser DE; Romero P
    Cancer Res; 2009 Oct; 69(20):8085-93. PubMed ID: 19808957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients.
    Ayyoub M; Souleimanian NE; Godefroy E; Scotto L; Hesdorffer CS; Old LJ; Valmori D
    Clin Immunol; 2006; 118(2-3):188-94. PubMed ID: 16368270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity.
    Valmori D; Scheibenbogen C; Dutoit V; Nagorsen D; Asemissen AM; Rubio-Godoy V; Rimoldi D; Guillaume P; Romero P; Schadendorf D; Lipp M; Dietrich PY; Thiel E; Cerottini JC; Liénard D; Keilholz U
    Cancer Res; 2002 Mar; 62(6):1743-50. PubMed ID: 11912149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
    Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
    J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
    Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
    J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
    Hasegawa K; Noguchi Y; Koizumi F; Uenaka A; Tanaka M; Shimono M; Nakamura H; Shiku H; Gnjatic S; Murphy R; Hiramatsu Y; Old LJ; Nakayama E
    Clin Cancer Res; 2006 Mar; 12(6):1921-7. PubMed ID: 16551878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma.
    Valmori D; Dutoit V; Rubio-Godoy V; Chambaz C; Liénard D; Guillaume P; Romero P; Cerottini JC; Rimoldi D
    Cancer Res; 2001 Jan; 61(2):509-12. PubMed ID: 11212242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype.
    Sensi M; Nicolini G; Zanon M; Colombo C; Molla A; Bersani I; Lupetti R; Parmiani G; Anichini A
    Cancer Res; 2005 Jan; 65(2):632-40. PubMed ID: 15695408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
    Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
    Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
    Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
    Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.
    Andersen MH; Pedersen LO; Capeller B; Bröcker EB; Becker JC; thor Straten P
    Cancer Res; 2001 Aug; 61(16):5964-8. PubMed ID: 11507035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid and Continued T-Cell Differentiation into Long-term Effector and Memory Stem Cells in Vaccinated Melanoma Patients.
    Gannon PO; Baumgaertner P; Huber A; Iancu EM; Cagnon L; Abed Maillard S; Maby-El Hajjami H; Speiser DE; Rufer N
    Clin Cancer Res; 2017 Jul; 23(13):3285-3296. PubMed ID: 27872103
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
    Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P
    Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
    Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
    J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.